cytoreduction


Also found in: Dictionary, Wikipedia.
Related to cytoreduction: Neoadjuvant, HIPEC

cytoreduction

 [si″to-re-duk´shun]
1. decrease in the number of cells, such as in a tumor.

cy·to·re·duc·tive ther·a·py

therapy with the intention of reducing the number of cells in a lesion, usually a malignancy.
Synonym(s): cytoreduction

cytoreduction

(sīt″ō-rĕ-dŭk′shŭn) [″ + ″]
Cellular killing, usually of cancerous cell clones, with chemotherapy.
cytoreductive (-dŭk′-tĭv), adjective
References in periodicals archive ?
Optimal cytoreduction was defined as either no residual disease or residual disease less than 1cm in maximal dimension at the end of the surgery.
Eric Klein: The modelling of cytoreduction and PSA effects
(32) A favorable outcome is highly correlated with completeness of cytoreduction, (33) yet complete cytoreduction is difficult to achieve, especially in patients with diffuse abdominal disease.
She and her colleagues at Memorial Sloan-Kettering Cancer Center, New York, retrospectively reviewed outcomes in 50 patients undergoing secondary cytoreduction following a recurrence of their ovarian cancer.
Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
The current standard of care for ovarian cancer, after cytoreduction surgery is chemotherapy with six cycles of either cisplatin or carboplatin and paclitaxel for any cancer stage II or above.
Surgical cytoreduction for disseminated benign disease after open power uterine morcellation.
Surgery provides a definite tissue diagnosis, enable staging, and can be an R0 re-section or optimum cytoreduction.
Pai and colleagues report a small randomized controlled trial (RCT) examining whether men who receive 6 months of neoadjuvant androgen deprivation therapy for cytoreduction recover faster whether they receive a monthly luteinizing hormone-releasing hormone agonist (LHRHa) or an injection every 3 months.[sup.1] Unfortunately, due to accrual and eligibility issues, the authors were not able to complete the study in a timely manner and only 46 of the planned 100 patients were available for data analysis.
There was a lack of prescribed secondary- or tertiary-line chemotherapy, and the type of surgery was not considered--optimal versus sub-optimal and secondary cytoreduction. New drugs have come along.
The Norton-Simon model would predict that HDC after cytoreduction would represent optimal scheduling for dose intensification (10-12).